Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone617-417-5868
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees30
Next Earnings DateN/A
OptionableNot Optionable
I-Mab (NASDAQ:BDTX) Frequently Asked Questions
What is I-Mab's stock symbol?
I-Mab trades on the NASDAQ under the ticker symbol "BDTX."
What price target have analysts set for BDTX?
4 brokerages have issued 1-year target prices for I-Mab's stock. Their forecasts range from $42.00 to $50.00. On average, they expect I-Mab's share price to reach $46.33 in the next twelve months. This suggests a possible upside of 44.8% from the stock's current price. View Analyst Price Targets for I-Mab.
What is the consensus analysts' recommendation for I-Mab?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for I-Mab.
Has I-Mab been receiving favorable news coverage?
Headlines about BDTX stock have trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. I-Mab earned a media sentiment score of -4.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for I-Mab.
Who are some of I-Mab's key competitors?
Some companies that are related to I-Mab include Repligen (RGEN), Spark Therapeutics (ONCE), bluebird bio (BLUE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO), Audentes Therapeutics (BOLD), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Alector (ALEC) and Bill.com (RVMD).
What other stocks do shareholders of I-Mab own?
Who are I-Mab's key executives?
I-Mab's management team includes the folowing people:
- Dr. David M. Epstein, Pres, CEO & Director (Age 61)
- Dr. Elizabeth Buck Ph.D., Exec. VP of Discovery & Translational Services (Age 45)
- Mr. Thomas Leggett, Chief Financial Officer (Age 43)
- Mr. Brent Hatzis-Schoch Esq., J.D., COO & Gen. Counsel (Age 55)
- Dr. Christopher D. Roberts, Chief Scientific Officer (Age 50)
When did I-Mab IPO?
(BDTX) raised $151 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager.
When does the company's quiet period expire?
I-Mab's quiet period expires on Tuesday, March 10th. I-Mab had issued 10,586,316 shares in its initial public offering on January 30th. The total size of the offering was $201,140,004 based on an initial share price of $19.00. During the company's quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
How do I buy shares of I-Mab?
Shares of BDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is I-Mab's stock price today?
One share of BDTX stock can currently be purchased for approximately $32.00.
How big of a company is I-Mab?
What is I-Mab's official website?
How can I contact I-Mab?
I-Mab's mailing address is 139 MAIN STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-417-5868.
MarketBeat Community Rating for I-Mab (NASDAQ BDTX)
MarketBeat's community ratings are surveys of what our community members think about I-Mab and other stocks. Vote "Outperform" if you believe BDTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
